Trial Profile
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 Dec 2015 New trial record